CoChat

The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1receptor antagonism ? or inverse agonism ? as potential obesity treatment and other therapeutic use

Open access
Xie, S., Furjanic, M. A., Ferrara, J. J., McAndrew, N. R., Ardino, E. L., Ngondara, A., Bernstein, Y., Thomas, K. J., Kim, E., Walker, J. M., Nagar, S., Ward, S. J., Raffa, R. B. · 2007 · Journal of Clinical Pharmacy and Therapeutics
Cited by 82

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over-activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders. Towards this end, antagonists of cannabinoid receptors have been designed through rational drug discovery efforts. Devoid of the abuse concerns that confound and impede the use of cannabinoid receptor agonists for legitimate medical purposes, investigation of the use of cannabinoid receptor antagonists as possible pharmacotherapeutic agents is currently being actively investigated. The compound furthest along this pathway is rimonabant, a selective CB(1) (cannabinoid receptor subtype 1) antagonist, or inverse agonist, approved in the European Union and under regulatory review in the United States for the treatment of obesity. This article summarizes the basic science of the endocannabinoid system and the therapeutic potential of cannabinoid receptor antagonists, with emphasis on the treatment of obesity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2710.2007.00817.x

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 82

Metadata

Authors
Xie, S., Furjanic, M. A., Ferrara, J. J., McAndrew, N. R., Ardino, E. L., Ngondara, A., Bernstein, Y., Thomas, K. J., Kim, E., Walker, J. M., Nagar, S., Ward, S. J., & Raffa, R. B.
Venue
Journal of Clinical Pharmacy and Therapeutics
Published
2007-06
Volume
32
Issue
3
Pages
209-231
ISSN
  • 0269-4727 (ISSN-L)
  • 1365-2710
OpenAlex
W1971036356
Cited by
82
References
17
FWCI
5.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1receptor antagonism ? or inverse agonism ? as potential obesity treatment and other therapeutic use. https://app.cochat.ai/papers/10.1111/j.1365-2710.2007.00817.x
The paper
Xie, S., Furjanic, M. A., Ferrara, J. J., McAndrew, N. R., Ardino, E. L., Ngondara, A., Bernstein, Y., Thomas, K. J., Kim, E., Walker, J. M., Nagar, S., Ward, S. J., & Raffa, R. B. (2007). The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1receptor antagonism ? or inverse agonism ? as potential obesity treatment and other therapeutic use. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1111/j.1365-2710.2007.00817.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.